{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:32:29Z","timestamp":1788323549246,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.dsx.2024.103126","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T01:45:56Z","timestamp":1726883156000},"page":"103126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Xuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7060-1731","authenticated-orcid":false,"given":"Fan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.dsx.2024.103126_bib1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dsx.2024.103126_bib2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dsx.2024.103126_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001311","article-title":"Regional difference in the susceptibility of non-alcoholic fatty liver disease in China","volume":"8","author":"Xia","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.dsx.2024.103126_bib4","article-title":"Rationale and design of RNAFH study: effect of rosuvastatin (10 mg\/d) on nonalcoholic fatty liver in metabolic syndrome patients without overt diabetes evaluated by (1)H-magnetic resonance spectroscopy","volume":"2016","author":"Ping","year":"2016","journal-title":"Internet J Endocrinol"},{"issue":"2","key":"10.1016\/j.dsx.2024.103126_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(00)00407-X","article-title":"Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes","volume":"153","author":"Isusi","year":"2000","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.dsx.2024.103126_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2174\/15701611113119990009","article-title":"Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report","volume":"12","author":"Kargiotis","year":"2014","journal-title":"Curr Vasc Pharmacol"},{"issue":"11","key":"10.1016\/j.dsx.2024.103126_bib7","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1872-034X.2012.01034.x","article-title":"Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study","volume":"42","author":"Nakahara","year":"2012","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.dsx.2024.103126_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12916-022-02288-2","article-title":"Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)","volume":"20","author":"Cho","year":"2022","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.dsx.2024.103126_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dsx.2024.103126_bib10","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin Nutr"},{"issue":"26","key":"10.1016\/j.dsx.2024.103126_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033981","article-title":"Statins on nonalcoholic fatty liver disease: a systematic review and meta-analysis of 14 RCTs","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"10.1016\/j.dsx.2024.103126_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040632","article-title":"Metabolic imaging in non-alcoholic fatty liver disease: applications of magnetic resonance spectroscopy","volume":"10","author":"Thiagarajan","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.dsx.2024.103126_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition. A consensus statement from the international diabetes federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.dsx.2024.103126_bib14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/jmri.21542","article-title":"Magnetic resonance imaging and spectroscopy for monitoring liver steatosis","volume":"28","author":"Cowin","year":"2008","journal-title":"J Magn Reson Imag"},{"issue":"1","key":"10.1016\/j.dsx.2024.103126_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.dsx.2024.103126_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol"},{"issue":"15","key":"10.1016\/j.dsx.2024.103126_bib17","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1074\/jbc.REV119.008897","article-title":"The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease","volume":"295","author":"Zhao","year":"2020","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.dsx.2024.103126_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137720","article-title":"Optical isomers of atorvastatin, rosuvastatin and fluvastatin enantiospecifically activate pregnane X receptor PXR and induce CYP2A6, CYP2B6 and CYP3A4 in human hepatocytes","volume":"10","author":"Korhonova","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.dsx.2024.103126_bib19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/2047487315598710","article-title":"Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: results from the VOYAGER meta-analysis","volume":"23","author":"Karlson","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.dsx.2024.103126_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40264-014-0169-4","article-title":"Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases","volume":"37","author":"Kostapanos","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.dsx.2024.103126_bib21","article-title":"Statins as a potential treatment for non-alcoholic fatty liver disease: target deconvolution using protein-protein interaction network analysis","author":"Mahmoudi","year":"2023","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.dsx.2024.103126_bib22","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.dsx.2024.103126_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174319","article-title":"Ferroptosis as a new therapeutic opportunity for nonviral liver disease","volume":"908","author":"Jia","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.dsx.2024.103126_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","article-title":"Ferroptosis: death by lipid peroxidation","volume":"26","author":"Yang","year":"2016","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.dsx.2024.103126_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154752","article-title":"Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes","volume":"121","author":"Ciardullo","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.dsx.2024.103126_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"10","key":"10.1016\/j.dsx.2024.103126_bib27","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dsx.2024.103126_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.dsx.2024.103126_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2024.103126_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2174\/1570161118666201015152921","article-title":"Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis in military personnel. Do genetics play a role?","volume":"19","author":"Sfikas","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"issue":"6","key":"10.1016\/j.dsx.2024.103126_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061216","article-title":"Association of metabolomic change and treatment response in patients with non-alcoholic fatty liver disease","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.dsx.2024.103126_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","article-title":"The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease","volume":"47","author":"Pastori","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.dsx.2024.103126_bib33","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: Post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402124001875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402124001875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T14:17:18Z","timestamp":1733149038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402124001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1871402124001875"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2024.103126","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2024.103126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103126"}}